(Q34538293)

English

Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial (English)

1 reference

Europe PubMed Central

2 August 2017

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Hyung Joon Yim

1

1 reference

Europe PubMed Central

2 August 2017

Yeon Seok Seo

2

1 reference

Europe PubMed Central

2 August 2017

Eileen L Yoon

3

1 reference

Europe PubMed Central

2 August 2017

Chang Wook Kim

4

1 reference

Europe PubMed Central

2 August 2017

Chang Don Lee

5

1 reference

Europe PubMed Central

2 August 2017

Sang Hoon Park

6

1 reference

Europe PubMed Central

2 August 2017

Myung Seok Lee

7

1 reference

Europe PubMed Central

2 August 2017

Choong Kee Park

8

1 reference

Europe PubMed Central

2 August 2017

Hee Bok Chae

9

1 reference

Europe PubMed Central

2 August 2017

Moon Young Kim

10

1 reference

Europe PubMed Central

2 August 2017

Soon Koo Baik

11

1 reference

Europe PubMed Central

2 August 2017

Yun Soo Kim

12

1 reference

Europe PubMed Central

2 August 2017

Ju Hyun Kim

13

1 reference

Europe PubMed Central

2 August 2017

Jung Il Lee

14

1 reference

Europe PubMed Central

2 August 2017

Jin Woo Lee

15

1 reference

Europe PubMed Central

2 August 2017

Sun Pyo Hong

16

1 reference

Europe PubMed Central

2 August 2017

Soon Ho Um

17

1 reference

Europe PubMed Central

2 August 2017

publication date

1 February 2013

1 reference

Europe PubMed Central

2 August 2017

Liver International

1 reference

Europe PubMed Central

2 August 2017

33

1 reference

Europe PubMed Central

2 August 2017

2

1 reference

Europe PubMed Central

2 August 2017

244-254

1 reference

Europe PubMed Central

2 August 2017

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

[Hepatitis B virus genetic diversity and mutant].

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Tbe complete nudeotide sequences of the cloned hepatitis B vims DNA; subtype adr and adw

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12036

21 January 2018

Identifiers

10.1111/LIV.12036

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34538293&oldid=1984682453"